MiNK Secures $1.1M PRAME-Targeted iNKT Collaboration, Q4 Loss Forecast
MiNK Therapeutics secured a C-Further collaboration to advance a PRAME-targeted TCR-engineered iNKT cell therapy for pediatric sarcomas and AML with up to $1.1 million in non-dilutive funding and double-digit downstream revenue participation. The company will report Q4 2025 results on March 17, with analysts forecasting a ($0.68) per-share loss.
1. Collaboration with C-Further
MiNK secured selection in the C-Further pediatric oncology program to advance its PRAME-targeted TCR-engineered iNKT cell therapy, focusing on sarcomas and AML. The collaboration provides up to $1.1 million in non-dilutive funding tied to IND-enabling milestones and grants MiNK a double-digit share of future commercial revenues under a non-exclusive agreement.
2. Q4 2025 Earnings Forecast
MiNK is scheduled to report its Q4 2025 financial results on March 17 before market open. Analysts anticipate a ($0.68) per-share loss, reflecting continued investment in R&D and early-stage pipeline development.